CD8A and neoplasm: These vaccines, including TriMix, BNT111, mRNA-4157, and BNT122, encode not only tumor antigens but also immunomodulatory molecules and inflammatory cytokines.362 A phase II trial highlighted a robust CD8 + T-cell response elicited by the TriMix vaccine, which includes a tumor-associated antigen (TAA) mRNA, in stage III and IV melanoma patients.